Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

141. Comparison of rates of adverse events in adolescent and adult women undergoing medical abortion: population register based study.

Comparison of rates of adverse events in adolescent and adult women undergoing medical abortion: population register based study. OBJECTIVE: To determine the risks of short term adverse events in adolescent and older women undergoing medical abortion. DESIGN: Population based retrospective cohort study. SETTING: Finnish abortion register 2000-6. PARTICIPANTS: All women (n = 27,030) undergoing medical abortion during 2000-6, with only the first induced abortion analysed for each woman. MAIN (...) OUTCOME MEASURES: Incidence of adverse events (haemorrhage, infection, incomplete abortion, surgical evacuation, psychiatric morbidity, injury, thromboembolic disease, and death) among adolescent (<18 years) and older (≥ 18 years) women through record linkage of Finnish registries and genital Chlamydia trachomatis infections detected concomitantly with abortion and linked with data from the abortion register for 2004-6. RESULTS: During 2000-6, 3024 adolescents and 24,006 adults underwent at least

BMJ2011 Full Text: Link to full Text with Trip Pro

142. Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study)

Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study) 21146678 2010 12 14 2011 02 08 2013 11 21 1879-1913 107 1 2011 Jan The American journal of cardiology Am. J. Cardiol. Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective (...) either 600 mg (n = 200) or 300 mg (n = 200) of clopidogrel, followed by a daily maintenance dose of 75 mg. The primary end point was the presence of major adverse cardiovascular events (combined death, myocardial infarction, acute neurologic event, stent thrombosis, and need for percutaneous or surgical revascularization of the target vessel) during hospitalization and at 30 days. The secondary end point was periprocedural vascular complications, major bleeding, and cardiac enzyme elevation

EvidenceUpdates2011

143. Literature review: do rapid response systems reduce the incidence of major adverse events in the deteriorating ward patient?

Literature review: do rapid response systems reduce the incidence of major adverse events in the deteriorating ward patient? 21029228 2010 11 18 2011 03 24 2010 11 18 1365-2702 19 23-24 2010 Dec Journal of clinical nursing J Clin Nurs Literature review: do rapid response systems reduce the incidence of major adverse events in the deteriorating ward patient? 3260-73 10.1111/j.1365-2702.2010.03394.x To conduct a literature review that explores the impact of rapid response systems on reducing (...) major adverse events experienced by deteriorating ward patients. Patients located on hospitals wards are frequently older, have multiple co-morbidities and are often at risk of life-threatening clinical deterioration. Rapid response systems have been developed and implemented to provide appropriate and timely intervention to these patients. A comprehensive review of the literature. This review used the rapid response systems framework recently developed by experts in the area. Medline, CINAHL

EvidenceUpdates2011

144. Association between recent stressful life events and prevalence of depression, anxiety and PTSD differs according to exposure to childhood adversity

Association between recent stressful life events and prevalence of depression, anxiety and PTSD differs according to exposure to childhood adversity Association between recent stressful life events and prevalence of depression, anxiety and PTSD differs according to exposure to childhood adversity | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Association between recent stressful life events and prevalence of depression, anxiety and PTSD differs according to exposure to childhood adversity Article Text Prevalence Association between recent stressful life

Evidence-Based Mental Health2011

145. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis

Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis Butalia S, Leung AA, Ghali WA, Rabi DM CRD summary The authors (...) concluded that the results suggested aspirin reduced the risk of major adverse cardiovascular events in patients with diabetes without cardiovascular disease, but that there also appeared to be higher rates of bleeding and gastrointestinal complications. The authors' conclusions reflect the evidence presented and are likely to be reliable. Authors' objectives To evaluate the benefits and harms of aspirin for the prevention of major adverse cardiovascular events in patients with diabetes. Searching

DARE.2011

146. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab (...) : a systematic literature review and meta-analysis of randomized controlled trials Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ CRD summary High-dose tocilizumab in combination with methotrexate as a treatment for rheumatoid arthritis was associated with a small but significant increase in adverse events and infection compared to controls; the effect was unclear for tocilizumab monotherapy. Limitations in study numbers and the review process mean that the results should be treated with caution. Authors

DARE.2011

147. Dronedarone (Multaq?): cardiovascular, hepatic and pulmonary adverse events ? new restrictions and monitoring requirements

Dronedarone (Multaq?): cardiovascular, hepatic and pulmonary adverse events ? new restrictions and monitoring requirements Dronedarone (Multaq▼): cardiovascular, hepatic and pulmonary adverse events – new restrictions and monitoring requirements Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Dronedarone (Multaq▼): cardiovascular, hepatic and pulmonary adverse events – new restrictions and monitoring requirements From: Published: 13 October 2011 Therapeutic area (...) (Permanent Atrial fibriLLAtion outcome Study using dronedarone on top of standard therapy) had been investigating the potential clinical benefit of dronedarone (added to standard therapy) in patients older than 65 years with permanent atrial fibrillation in the reduction of: major cardiovascular (CV) events (ie, stroke, systemic arterial embolism, myocardial infarction, or cardiovascular death) unplanned cardiovascular hospitalisation or death from any cause The study was prematurely terminated in July

MHRA Drug Safety Update2011

148. Dronedarone (Multaq?): cardiovascular, hepatic and pulmonary adverse events

Dronedarone (Multaq?): cardiovascular, hepatic and pulmonary adverse events Enzira/CSL Biotherapies and Viroflu/Inflexal V influenza vaccines and risk of febrile reactions in children under 5 years Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Enzira/CSL Biotherapies and Viroflu/Inflexal V influenza vaccines and risk of febrile reactions in children under 5 years From: Published: 13 October 2011 Therapeutic area: Use alternative vaccines in under 5s and report (...) suspected adverse reactions Article date: October 2011 Prescribers are reminded that Enzira and CSL Biotherapies generic influenza vaccines (both manufactured by CSL and marketed by Pfizer) should not be given to children younger than 5 years. These vaccines are not authorised for use in this age-group after the increased risk of febrile convulsions observed in Australia last year (see ). CSL also supplies starting materials for the manufacture of another flu vaccine, Viroflu and Inflexal V (both

MHRA Drug Safety Update2011

149. Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis

Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis Smits NA, Duru N, Bijlsma JW, Jacobs JW CRD summary The review concluded that intravenous glucocorticoid pulse therapy resulted in a high adverse event rate; cardiovascular adverse events were (...) the most commonly reported. The review had methodological and data limitations that limit the reliability of the authors’ conclusions. Authors' objectives To determine the adverse events associated with intravenous pulse glucocorticoids for inflammatory diseases. Searching PubMed, EMBASE and The Cochrane Library were searched to October 2009 for articles published in English. Full search strategies were reported. Reference lists of retrieved studies were searched. Study selection Full text randomised

DARE.2011

150. Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials

Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after (...) percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Sethi A, Bahekar A, Doshi H, Bhuriya R, Bedi U, Singh S, Khosla S CRD summary Routine early tirofiban use plus aspirin and clopidogrel in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention may have reduced major adverse cardiovascular events without increasing major bleeding rates. The conclusions were not definitive due to limited

DARE.2011

151. Systematic review: Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel

Systematic review: Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel | Evidence-Based Medicine This site uses cookies (...) with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel Article Text Prognosis Systematic review Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel Andrea H Ramirez 1 , Jessica T Delaney 1 , Alan R Shuldiner 2 Statistics from Altmetric.com No Altmetric data

Evidence-Based Medicine (Requires free registration)2011

152. Risk of Serious Adverse Cardiovascular (CV) Events with Varenicline (Champix) Comment on Systematic Review and Meta?analysis

Risk of Serious Adverse Cardiovascular (CV) Events with Varenicline (Champix) Comment on Systematic Review and Meta?analysis

RxFiles2011

153. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB

Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB 20627913 2010 07 14 2010 08 05 2013 11 21 1468-3296 65 7 2010 Jul Thorax Thorax Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. 582-7 10.1136/thx.2009.125054 Treatment for latent tuberculosis infection with isoniazid (...) for 9 months (9INH) has poor completion and serious adverse events, while treatment for 4 months with daily rifampin (4RIF) has significantly higher completion and fewer adverse events. To compare the health system costs of 4RIF and 9INH. In a randomised trial conducted in five Canadian centres, one Brazilian and one Saudi Arabian centre, consenting subjects were randomised to receive 4RIF or 9INH. Health system costs were estimated from healthcare utilisation including scheduled and unscheduled

EvidenceUpdates2010

154. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study

Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study 19581281 2010 05 25 2010 07 16 2016 11 25 1468-2060 69 6 2010 Jun Annals of the rheumatic diseases Ann. Rheum. Dis. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. 1044-8 10.1136/ard.2008.106617 To evaluate toxicity (...) profiles in patients with rheumatoid arthritis (RA) treated either according to an intensive or a conventional treatment strategy approach with methotrexate (MTX) and to study factors associated with MTX-related toxicity. Data were used from the Computer-Assisted Management in Early Rheumatoid Arthritis (CAMERA) study, in which clinical efficacy of an intensive treatment strategy with MTX was more beneficial than a conventional treatment strategy approach. In this study, data on adverse events (AEs

EvidenceUpdates2010

155. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up

A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up 19778920 2010 04 28 2010 06 08 2014 03 10 1468-201X 96 9 2010 May Heart (British Cardiac Society) Heart A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. 662-7 10.1136/hrt.2009.177162 Few reports described (...) . Before the first angioplasty patients were randomly assigned to three different strategies: culprit vessel angioplasty-only (COR group); staged revascularisation (SR group) and simultaneous treatment of non-IRA (CR group). During a mean follow-up of 2.5 years, 42 (50.0%) patients in the COR group experienced at least one major adverse cardiac event (MACE), 13 (20.0%) in the SR group and 15 (23.1%) in the CR group, p<0.001. Inhospital death, repeat revascularisation and re-hospitalisation occurred

EvidenceUpdates2010

156. Use of manometry for laryngeal mask airway reduces postoperative pharyngolaryngeal adverse events: a prospective, randomized trial

Use of manometry for laryngeal mask airway reduces postoperative pharyngolaryngeal adverse events: a prospective, randomized trial 20179502 2010 02 24 2010 03 30 2015 11 19 1528-1175 112 3 2010 Mar Anesthesiology Anesthesiology Use of manometry for laryngeal mask airway reduces postoperative pharyngolaryngeal adverse events: a prospective, randomized trial. 652-7 10.1097/ALN.0b013e3181cf4346 Adverse events such as pharyngolaryngeal complications are indicators of quality patient care. Use (...) Journal Article Randomized Controlled Trial United States Anesthesiology 1300217 0003-3022 AIM IM Adolescent Adult Aged Aged, 80 and over Ambulatory Surgical Procedures Anesthesia, Inhalation Anesthesia, Intravenous Deglutition Disorders etiology prevention & control Dysphonia etiology prevention & control Female Humans Intubation, Intratracheal adverse effects methods Laryngeal Masks Larynx injuries Male Manometry methods Middle Aged Monitoring, Intraoperative Pharyngitis etiology prevention

EvidenceUpdates2010

157. Associations between renal duplex parameters and adverse cardiovascular events in the elderly: a prospective cohort study

Associations between renal duplex parameters and adverse cardiovascular events in the elderly: a prospective cohort study 20116688 2010 02 01 2010 02 22 2016 12 03 1523-6838 55 2 2010 Feb American journal of kidney diseases : the official journal of the National Kidney Foundation Am. J. Kidney Dis. Associations between renal duplex parameters and adverse cardiovascular events in the elderly: a prospective cohort study. 281-90 10.1053/j.ajkd.2009.10.044 Atherosclerotic renovascular disease (...) is associated with an increased risk of cardiovascular disease (CVD) events. This study examines associations between Doppler-derived parameters from the renal artery and renal parenchyma and all-cause mortality and fatal and nonfatal CVD events in a cohort of elderly Americans. Cohort study. A subset of participants from the Cardiovascular Health Study (CHS). Through an ancillary study, 870 (70% recruitment) Forsyth County, NC, CHS participants consented to undergo renal duplex sonography to define

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

158. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study 20039804 2010 01 11 2010 01 27 2010 01 11 1537-6613 201 3 2010 Feb 01 The Journal of infectious diseases J. Infect. Dis. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection (...) on adverse events of anti-HIV drugs (D:A:D) study. 318-30 10.1086/649897 BACKGROUND. The risk of myocardial infarction (MI) in patients with human immunodeficiency virus (HIV) infection has been assessed in 13 anti-HIV drugs in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. METHODS. Poisson regression models were adjusted for cardiovascular risk factors, cohort, calendar year, and use of other antiretroviral drugs and assessed the association between MI risk and cumulative (per

EvidenceUpdates2010

160. Meta-analysis of adverse cardiovascular events associated with echocardiographic contrast agents

Meta-analysis of adverse cardiovascular events associated with echocardiographic contrast agents Meta-analysis of adverse cardiovascular events associated with echocardiographic contrast agents Meta-analysis of adverse cardiovascular events associated with echocardiographic contrast agents Khawaja OA, Shaikh KA, Al-Mallah MH CRD summary This review found that evidence suggested that use of contrast agents with echocardiography was safe and not associated with an increase in incidence (...) affected the review, although serious adverse event reporting was more likely to have been published. The methods of data extraction were aimed at reducing reviewer error or bias; study selection methods were not described. The authors did not appear to assess study quality, so it was difficult to comment on the validity of included data. Tests showed considerable heterogeneity between studies and it may not have been appropriate to combine data, although all studies individually showed no increased

DARE.2010